CHARACTERISTICS OF PERIOPERATIVE IMMUNOTHERAPY CLINICAL TRIALS IN NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW

M.D. GIL-SIERRA¹, <u>C. MORENO RAMOS²</u>, M.D.P. BRICEÑO-CASADO¹, R. CASTILLEJO-GARCIA¹, J. CORDERO-RAMOS¹

¹SERVICIO EXTREMEÑO DE SALUD, SERVICIOS CENTRALES. SUBDIRECCIÓN DE FARMACIA, MERIDA, SPAIN. ²SERVICIO EXTREMEÑO DE SALUD, SERVICIOS CENTRALES. SUBDIRECCIÓN DE FARMACIA., MÉRIDA- BADAJOZ, SPAIN.

 2SPD-007
 L01 – Antineoplastic agents


 BACKGROUND
 *

 * Recently, several immunotherapy regimens were evaluated against chemotherapy (CT) as perioperative treatment for resectable non-small-cell lung cancer (rNSCLC). Analysing randomised clinical trials (RCTs) characteristics is essential for future reliable indirect comparisons between schemes.

To perform a systematic search and evaluation of RCTs characteristics about the use of perioperative



immunotherapies for rNSCLC



Sistematic search in Pubmed[®] (September 17, 2024)

MATERIAL AND METHODS

- Search strategy with "Randomized Controlled Trial" filter: [Perioperative Resectable Non-Small-Cell Lung Cancer]
- ✓ Selection: Phase III RCTs with immunotherapies as perioperative treatment of rNSCLC and event-free survival (EFS)
- ✓ The rest of studies were excluded.
- ✓ RCTs characteristics assessed: populations (baseline factors), intervention arm (exposure time and schemes used), comparator arm (differences in common drug regimen) and other study design aspects.

Results of bibliographic review: 55 results 51 results excluded

RESULTS

4 RCTs included

Perioperative (P-) immunotherapies found

P-toripalimab P-pembrolizumab P-nivolumab P-durvalumab

✓ 9 without design of RCTs

- ✓ 39 assessed different interventions
- ✓ 2 with different clinical context
- ✓ 1 evaluated different outcomes than EFS



Intervention and comparator arm

- P-toripalimab presented an adjuvant CT cycle in arms (3 neoadjuvant toripalimab+CT cycles with 1 adjuvant toripalimab+CT cycle followed by adjuvant toripalimab)
 The remaining treatments contained 4 neoadjuvant immunotherapeutic agent+CT cycles with adjuvant immunotherapy.
- All perioperative schemes included carboplatin- or cisplatin-based regimens in CT, except P-pembrolizumab (only cisplatin therapies)

Differences in baseline factors



- ➢ Patients with ≥65 years (31.2% in P-toripalimab vs 45-56% in rest)
 ➢ Squamous histology (77.7% in P-toripalimab vs 43-51% in others)
 ➢ Cancer stage IIIA-IIIB (99.2% in P-toripalimab vs 64-70% in rest)
- > N2 stage (70% in P-toripalimab vs 39%-45% in others)

Other study design aspects

Time of adjuvant exposure: 365 days for P-nivolumab vs 273-336 for the rest
 Patient follow-up: 11.7 months for P-durvalumab vs 18-25 months for others

CONCLUSION

- 1. RCT of P-toripalimab presented differences in populations, intervention and control arms compared to the rest of immunotherapies.
- 2. Only P-pembrolizumab included exclusively cisplatinum-based regimens.
- 3. P-nivolumab required a longer adjuvant exposure time.
- 4. P-durvalumab developed the lowest patient follow-up.

